Ranolazine Cardioprotection in PCI
| Status: | Terminated |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2012 |
| End Date: | April 2014 |
The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker
release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).
release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).
Ranolazine has been demonstrated to decrease angina, ischemia on perfusion imaging, improve
diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced
cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial
fibrillation. It has not been studied as an acute cardioprotective agent in percutaneous
coronary intervention (PCI).
We hypothesize that upfront administration of Ranolazine could decrease the myocardial
injury associated with PCI due to all the factors listed above (i.e. precondition the
myocardium). We plan to screen all patients scheduled for an elective coronary angiogram.
Those who meet criteria and consent will be randomized to either receive Ranolazine or
placebo twice a day for 3 days leading up to the PCI.
diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced
cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial
fibrillation. It has not been studied as an acute cardioprotective agent in percutaneous
coronary intervention (PCI).
We hypothesize that upfront administration of Ranolazine could decrease the myocardial
injury associated with PCI due to all the factors listed above (i.e. precondition the
myocardium). We plan to screen all patients scheduled for an elective coronary angiogram.
Those who meet criteria and consent will be randomized to either receive Ranolazine or
placebo twice a day for 3 days leading up to the PCI.
Inclusion Criteria:
- Age 18 or older
- Patients undergoing Coronary Angiography with possible PCI
- Able and willing to give consent
- Able to read and write English
Exclusion Criteria:
- Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary
Syndromes (ACS)
- History of Allergy to Ranolazine
- Pregnant or Nursing
- Currently taking Ranolazine
We found this trial at
1
site
Kettering Medical Center Our flagship hospital, Kettering Medical Center, stands proudly in Kettering, Ohio. From...
Click here to add this to my saved trials
